SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

Jan 13
1 min read

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.

https://vimeo.com/1154109767

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight